Skip to main content
Top
Published in: Indian Journal of Pediatrics 1/2012

01-01-2012 | Symposium on Growth Hormone

History of Growth Hormone Therapy

Author: Robert M. Blizzard

Published in: Indian Journal of Pediatrics | Issue 1/2012

Login to get access

Abstract

The first human to receive GH therapy was in 1956; it was of bovine origin and was given for 3 wk for metabolic balance studies revealing no effects. By 1958, three separate laboratories utilizing different extraction methods retrieved hGH from human pituitaries, purified it and used for clinical investigation. By 1959 presumed GHD patients were being given native hGH collected and extracted by various methods. Since 1 mg of hGH was needed to treat one patient per day, >360 human pituitaries were needed per patient per year. Thus, the availability of hGH was limited and was awarded on the basis of clinical research protocols approved by the National Pituitary Agency (NPA) established in 1961. hGH was dispensed and injected on a milligram weight basis with varied concentrations between batches from 0.5 units/mg to 2.0 units/mg of hGH. By 1977 a centralized laboratory was established to extract all human pituitaries in the US, this markedly improved the yield of hGH obtained and most remarkably, hGH of this laboratory was never associated with Creutzfeld-Jacob disease (CJD) resulting from the injection of apparently prior- contaminated hGH produced years earlier. However, widespread rhGH use was not possible even if a pituitary from each autopsy performed in the US was collected, this would only permit therapy for about 4,000 patients. Thus, the mass production of rhGH required the identification of the gene structure of the hormone, methodology that began in 1976 to make insulin by recombinant technology. Serendipity was manifest in 1985 when patients who had received hGH years previously were reported to have died of CJD. This led to the discontinuation of the distribution and use of hGH, at a time when a synthetic rhGH became available for clinical use. The creation of a synthetic rhGH was accompanied by unlimited supplies of hGH for investigation and therapy. However, the appropriate use and the potential abuse of this hormone are to be dealt with. The illegitimate use of rhGH, unequivocally the abuse by athletes is, and should be, of primary concern to society and should be halted. The abuse of prescribing rhGH in an attempt to retard the aging process also should receive attention.
Literature
1.
go back to reference Blizzard RM. The incidence of growth hormone deficiency: Does anyone know? Growth Genet Horm. 1985;1:4. Blizzard RM. The incidence of growth hormone deficiency: Does anyone know? Growth Genet Horm. 1985;1:4.
2.
go back to reference Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18:901–3.PubMedCrossRef Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18:901–3.PubMedCrossRef
3.
go back to reference Blizzard RM. Growth hormone deficiency (GHD) and GHD-like syndromes. In: Moiller EE, Cocoki D, Locatellin V, eds. Advances in growth hormone and growth factor research. Roma-Milano: Pythagora Press; 1989. pp. 285–98. Blizzard RM. Growth hormone deficiency (GHD) and GHD-like syndromes. In: Moiller EE, Cocoki D, Locatellin V, eds. Advances in growth hormone and growth factor research. Roma-Milano: Pythagora Press; 1989. pp. 285–98.
4.
go back to reference Blizzard RM. The past, present and future of pituitary growth hormone. Am J Dis Child. 1963;106:439–40.PubMed Blizzard RM. The past, present and future of pituitary growth hormone. Am J Dis Child. 1963;106:439–40.PubMed
5.
go back to reference Report of the 54th Ross Conference on Pediatric Research. Human Pituitary Growth Hormone. Blizzard RM. ed. Ross Laboratories; 1966. Report of the 54th Ross Conference on Pediatric Research. Human Pituitary Growth Hormone. Blizzard RM. ed. Ross Laboratories; 1966.
6.
go back to reference Utiger RD, Parker ML, Daughaday WH. Studies on human growth hormone II. The physiological disposition and metabolic fate of human growth hormone in man. J Clin Invest. 1962;41:254–61.PubMedCrossRef Utiger RD, Parker ML, Daughaday WH. Studies on human growth hormone II. The physiological disposition and metabolic fate of human growth hormone in man. J Clin Invest. 1962;41:254–61.PubMedCrossRef
7.
go back to reference Kowarski A, Thompson RG, Migeon CJ, Blizzard RM. Determination of integrated plasma concentrations and true secretion rates of human growth hormone. J Clin Endocrinol Metab. 1971;32:356–60.PubMedCrossRef Kowarski A, Thompson RG, Migeon CJ, Blizzard RM. Determination of integrated plasma concentrations and true secretion rates of human growth hormone. J Clin Endocrinol Metab. 1971;32:356–60.PubMedCrossRef
8.
go back to reference Hall SS. Invisible frontiers. New York, NY: Oxford University Press; 1987. Hall SS. Invisible frontiers. New York, NY: Oxford University Press; 1987.
9.
go back to reference Blizzard RM, et al. Pilot studies evaluating the role of hGH in the aging process. In: Underwood L, ed. Human growth hormone: progress and challenges. New York, NY: Marcel Dekker; 1987. pp. 231–9. Blizzard RM, et al. Pilot studies evaluating the role of hGH in the aging process. In: Underwood L, ed. Human growth hormone: progress and challenges. New York, NY: Marcel Dekker; 1987. pp. 231–9.
Metadata
Title
History of Growth Hormone Therapy
Author
Robert M. Blizzard
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Indian Journal of Pediatrics / Issue 1/2012
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-011-0609-4

Other articles of this Issue 1/2012

Indian Journal of Pediatrics 1/2012 Go to the issue

Scientific Letters to the Editor

Unexplained Crying Spells in a Young Child

Symposium on Growth Hormone

Biosimilar Growth Hormone